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Abstract
Background: The small molecule Eeyarestatin I (ESI) inhibits the endoplasmic reticulum (ER)-cytosol dislocation and
subsequent degradation of ERAD (ER associated protein degradation) substrates. Toxins such as ricin and Shiga/Shiga-like
toxins (SLTx) are endocytosed and trafficked to the ER. Their catalytic subunits are thought to utilise ERAD-like mechanisms
to dislocate from the ER into the cytosol, where a proportion uncouples from the ERAD process, recovers a catalytic
conformation and destroys their cellular targets. We therefore investigated ESI as a potential inhibitor of toxin dislocation.
Methodology and Principal Findings: Using cytotoxicity measurements, we found no role for ESI as an inhibitor of toxin
dislocation from the ER, but instead found that for SLTx, ESI treatment of cells was protective by reducing the rate of toxin
delivery to the ER. Microscopy of the trafficking of labelled SLTx and its B chain (lacking the toxic A chain) showed a delay in
its accumulation at a peri-nuclear location, confirmed to be the Golgi by examination of SLTx B chain metabolically labelled
in the trans-Golgi cisternae. The drug also reduced the rate of endosomal trafficking of diphtheria toxin, which enters the
cytosol from acidified endosomes, and delayed the Golgi-specific glycan modifications and eventual plasma membrane
appearance of tsO45 VSV-G protein, a classical marker for anterograde trafficking.
Conclusions and Significance: ESI acts on one or more components that function during vesicular transport, whilst at least
one retrograde trafficking pathway, that of ricin, remains unperturbed.
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Introduction
The plant toxin ricin and the bacterial Shiga and Shiga-like
toxins (SLTx) bind their receptors (glycoproteins/glycolipids
bearing exposed b1R4 linked galactose residues and the
sphingolipid Gb3 respectively) at the mammalian cell surface
and, after internalization by endocytosis, traffic in vesicular
carriers to the endoplasmic reticulum (ER) [1] (Figure 1). Here,
the toxic A chain (RTA) of ricin is reductively separated from its
receptor-binding B chain (RTB) [2], [3] and then unfolds and
partially inserts into the ER membrane [4]. This change in
structure is thought to mimic a misfolded membrane-associated
protein, allowing RTA to co-opt components of the ER-associated
protein degradation (ERAD) pathways that remove misfolded
proteins and orphan subunits from the ER in order to maintain
ER homeostasis [5], [6], [7].
Typical soluble ERAD substrates are unfolded in the ER lumen
and then extracted (dislocated) to the cytosol. During dislocation,
substrates are usually polyubiquitylated on internal lysine residues
by membrane integral E3 ubiquitin ligases such as HRD1. This
process provides tags for the cytosolic AAA (ATPase associated
with various cellular activities)-ATPase extraction motor p97/
VCP [8], [9], [10] and subsequently, after limited de-ubiquityla-
tion [11], [12], [13] for the proteasome [14], which is the terminal
destination for ERAD substrates. RTA can be co-immunoprecip-
itated with the Sec61 translocon [15], which is a putative
component of the dislocation machinery [16], and with EDEM,
an ERAD-associated mannosidase [17]. Furthermore, RTA
dislocation and cytotoxicity are sensitive to manipulation of
expression levels of SEL1L [18], a regulator of the HRD complex.
All these observations are consistent with use by RTA of
endogenous ERAD components. Post-dislocation, cytosolic triage
by molecular chaperones permits folding of a proportion of
cytosolic RTA to an active conformation and therefore at least a
fraction of dislocated RTA uncouples from the final ERAD step of
proteasomal degradation [19]. Refolded cytosolic RTA then
depurinates the large ribosomal subunit at one specific site [20],
resulting in cessation of protein synthesis and ultimately in cell
death. The RTA dislocation process in mammalian cells remains
otherwise unmapped. However, when expressed in the ER of the
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yeast Saccharomyces cerevisiae, RTA also utilizes components of the
yeast equivalent of the mammalian HRD1 complex (the Hrd1p
complex) for dislocation [21]. SLTx A chain (SLTxA) has identical
catalytic activity to RTA [22], and the holotoxin traffics to the ER
in a superficially similar manner to ricin [1] (Figure 1). It is widely
assumed that SLTxA also utilizes ERAD components for
dislocation to the cytosol. Little is known about the dislocation
process for SLTxA, other than interactions with ER chaperones
and Sec61 prior to dislocation [23], [24].
Mammalian major histocompatibility complex (MHC) Class I
heavy chains are normally expressed as type I membrane proteins
in the mammalian endoplasmic reticulum (ER), where they are
chaperoned until assembly with their partner b-microglobulin
chains [25], [26]. Each complex then binds a peptide derived from
proteins degraded in the cytosol that enters the ER lumen via
transporters associated with antigen processing (TAPs). The
assembled complex is trafficked via secretory vesicle carriers to
the plasma membrane, allowing peptide display to cells of the
immune system [27]. The cytomegalovirus immunoevasin protein
US11 down-regulates the expression of assembled complexes by
stimulating dislocation of folded MHC Class I molecules from the
ER to the cytosol. Here they are deglycosylated and then degraded
by the proteasome [28]. US11 interacts with numerous compo-
nents [29], [30] of the ER membrane integral HRD1 ubiquityla-
tion complex which is responsible for polyubiquitylating the MHC
Class I heavy chains during dislocation [31], [32]. This HRD
complex is fully functional in the absence of US11, dislocating
unassembled MHC Class I heavy chains [33] as well as other
Figure 1. Vesicular trafficking schemes. Following clathrin-independent endocytosis, the cytotoxic fractions of ricin and Shiga –like toxin (SLTx)
traffic to the ER via early endosmes (EE), the trans-Golgi network (TGN) and the Golgi apparatus to the endoplasmic reticulum (ER), where the ricin
subunits RTA and RTB are reductively separated. It is assumed that SLTxA chain is also separated from its B chain pentamer (SLTxB) in the ER. The
toxic RTA and SLTxA chains are thought to co-opt ERAD mechanisms to dislocate from the ER to the cytosol, where they are refolded to recover toxic
catalytic activity (ribosome modification). Diphtheria toxin (DTx) is endocytosed in a clathrin-dependent manner (hatched area) and enters the cytosol
from acidified endosomes. In the cytosol it is reduced, releasing the A chain (DTxA) which inactivates elongation factor 2. Blue boxes, areas/processes
affected by ESI: lower box, previously identified targets; upper box, this study. PM, plasma membrane.
doi:10.1371/journal.pone.0022713.g001
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ERAD substrates [5], [6]. The small molecule eeyarestatin I (ESI)
was identified in a high throughput screen for increased
fluorescence of mammalian cells expressing both an enhanced
green fluorescent protein (GFP)-Class I MHC heavy chain fusion
and the US11 gene product. ESI was subsequently shown to also
inhibit ERAD of orphan T cell receptor a (TCRa) subunits in the
absence of US11 [34]. The mechanism of ESI action is not yet
clear and the initial suggestion that it interfered with pre-
dislocation steps [34] was followed by evidence of an effect on a
post-dislocation step, namely p97-associated de-ubiquitylation
[35], [36], [37], a perturbation of co-translational translocation
at the ER, most likely through inhibition of Sec61 functions [38],
and formation of cross-linked adducts in the ER lumen between
protein disulphide isomerase (PDI) and an ERAD substrate [39].
The degradation of ERAD substrates normally requires both
ER dislocation and p97 activities, and since ESI has been reported
to perturb both processes [34], [35], [38], we investigated its
effects on the cytotoxicity of ER-trafficking toxins. We report here
that the later stages of the cytotoxic process for two toxins, ricin
and SLTx, are unaffected by ESI treatment (see Figure 1). This
suggests that in both cases the dislocation of their respective toxic
A chains across the ER membrane, and their subsequent delivery
into the cytosol, is unperturbed by the compound. However, we
find that SLTx toxicity is specifically reduced by ESI treatment.
We show that this effect results from interference with a much
earlier stage of the cytotoxic process, resulting in a delay in the
delivery of the holotoxin to the ER. Further studies revealed that
ESI can interfere with both the anterograde and retrograde
transport of vesicular cargoes through the endomembrane system
and we conclude that the ESI is most likely capable of perturbing
multiple cellular targets.
Results
ESI treatment protects HeLa cells from challenge with
SLTx but not ricin
The toxic A chains of ricin and SLTx have identical RNA N-
glycosidase activities, removing a single adenine residue from the
large ribosomal subunit at the site of interaction with elongation
factor complexes [20], [22], resulting in a cessation of protein
synthesis. Cytotoxicity can therefore be determined by comparing
the remaining levels of de novo protein synthesis capability in toxin-
challenged cells to those in non-toxin treated cells by pulsing toxin-
treated and control cells with radiolabelled amino-acids and
measuring their incorporation into acid-precipitable material
(proteins). HeLa cells were pretreated with ESI or its inactive
derivative ESR35 [38] for 1 h and then challenged for 1, 2 or 4 h
with dilutions of ricin or SLTx in medium containing ESI or ESR35
as appropriate, such that the compounds were present throughout
the toxin challenge period (see Methods). Remaining protein
synthesis at each toxin dilution was normalized to that of drug-
treated, but non-toxin treated, controls. For each individual
experiment a coeval control was performed, substituting DMSO
(the vehicle in which ESI and ESR35 were dissolved) for ESI or
ESR35, and here protein synthesis levels were normalized to
DMSO-treated, but not toxin-treated, controls. ESI treatment
alone had some toxicity in this assay, since it reduced the protein
synthesis ability of the cells (Figure 2A), but it had no obvious effect
on the cytotoxicity of ricin (Figure 2B). In contrast, ESI treatment
protected cells ,2.5 fold from challenge with SLTx (Figures 2C,
D). ESR35 had little or no effect in any of these assays.
These results initially suggested a mechanistic difference in the
ER to cytosol dislocation of RTA and SLTxA. ESI perturbs the
mammalian ubiquitin proteasome system (UPS) [35], so we
examined the role of the proteasome in SLTx cytotoxicity to
investigate whether this underlies its protective effect against SLTx
but not ricin whose A chain dislocates independently of the UPS
[21]. HeLa cells were challenged with SLTx in the presence of
clasto-Lactacystin b-lactone (cLb-l), an irreversible inhibitor of the
three proteolytic activities of the proteasome [40]. However,
despite a previous report that cLb-l sensitizes Vero cells slightly to
SLTx challenge [41], we saw no obvious effect in HeLa cells
(Figure 3A). The effectiveness of cLb-l was confirmed in vitro, by its
inhibition of proteasomal degradation of casein (Figure 3B).
Although the lack of obvious role for the proteasome in SLTx
toxicity to HeLa cells may reflect a cell-type specific difference in
the cytosolic fate of SLTxA, it should be noted that the previously
reported effect of cLb-l on SLTx cytotoxity was rather modest
[41]. Our results suggest that the cytotoxicity of SLTxA is not
strongly influenced by the UPS, and the protective effect of ESI is
most likely upstream of this process.
The mechanism of ESI -dependent protection against SLTx was
investigated further by examining the temporal profile of SLTx
intoxication. HeLa cells were treated with a saturating dose of
toxin (1 mg.ml21) for increasing lengths of time and the remaining
ability of the cells to synthesise proteins was measured. In such
experiments, there is a distinct lag before the first measurable loss
of protein synthesis ability, followed by a reduction in total cell
population protein synthesis ability whose (log) slope is determined
by the dislocation rate [42], [43]. If ESI reduces SLTxA
dislocation, this would be measurable by a reduction in the log
slope of the exponential phase, but the pre-cytosolic phase (lag)
should be unaltered. We found little or no difference in the half-
time (T1/2, the time taken to reduce remaining protein synthesis
ability by 50%) of the exponential phase. Strikingly, however, we
measured instead a distinct intoxication lag phase increase of ,20
minutes for ESI treatment, whilst ESR35 had no measurable effects
in these experiments (Figure 3C, D). This observation suggests that
the step affected by ESI most likely involves the delivery of the
toxin to the ER, and is hence upstream of dislocation (see Figure 1).
ESI treatment perturbs SLTx trafficking
To examine whether ESI treatment delays delivery of SLTx to
the ER, we applied fluorescently-labeled SLTx B chain pentamer
(SLTxB) or holotoxin to HeLa cells, and followed its intracellular
transport by confocal microscopy. Endocytosed recombinant
SLTxB traffics to the ER in the same way as SLTx holotoxin,
via early endosomes (EE), the trans-Golgi network (TGN) and the
Golgi stack to the ER [44]. In control cells treated with DMSO or
ESR35, fluorescently-labeled SLTxB (Cy3-SLTxB) accumulated at
a juxta-nuclear position within 40 minutes in those cells that had
taken up visible amounts of SLTxB (Figure 4A, Cy3-SLTxB), an
accumulation that has been previously shown to occur in the TGN
and the Golgi stack [45], [46]. In contrast, in ESI treated cells,
SLTxB was not observed in this location until 60 minutes
following application, showing a delay in the retrograde trafficking
of the toxin B chain. The same qualitative delay was also evident
when these experiments were repeated using fluorescently labeled
SLTx holotoxin (Figure 4A, Cy2-SLTx).
To define this delay biochemically we used SLTxB-(Sulf)2 [46],
a recombinant SLTxB chain pentamer whose subunits bear a C-
terminal tag that can be radiolabelled with [35S]-sulfate upon entry
to the trans-Golgi cisternae [47]. Relative to control cells treated
with DMSO, in ESI -treated cells an initial delay in [
35S]-labeling
of SLTxB-(Sulf)2 was observed, indicating delayed entry of
SLTxB-(Sulf)2 to the trans-Golgi cisternae. This was followed by
saturated labeling, suggesting a longer residence of the SLTxB-
(Sulf)2 pentamer in these cisternae upon ESI treatment (Figure 4B,
Eeyarestatin 1 Inhibits Intracellular Trafficking
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C). On the basis of these results, we conclude that both SLTx entry
to the trans-Golgi cisternae and subsequent egress from this
location are both inhibited by ESI treatment of cells.
ESI treatment protects cells from diphtheria toxin
challenge
SLTx is delivered to the trans-Golgi cisternae from an EE
compartment via the TGN [1], and therefore the temporal delay
in Golgi arrival might reflect reduced rates of trafficking at the
endosomal level. In contrast to ER trafficking toxins, following
endocytosis diphtheria toxin (DTx) translocates across the
endosomal membrane to enter the cytosol as the endosomal pH
drops to #5.3 (Figure 1) [48]. Strikingly, we found that ESI
treatment protected cells from DTx, particularly for shorter
intoxication times (Figure 5A, B). In contrast, ESR35 had no effect
for short intoxications, and may even have had a slight sensitizing
effect for longer toxin challenges (Figure 5A, B). The protective
effect of ESI again correlated with an increased lag prior to
cytosolic delivery of the toxin subunit, with little or no difference
measured in the toxin translocation rate (Figure 5C, D).
ESI treatment delays anterograde trafficking of tsO45VSV-
G-GFP from the ER
The retrograde trafficking defects resulting from ESI treatment
do not reflect a pleiotropic effect on all aspects of vesicular transport,
since the compound has no measureable effect on ricin cytotoxicity
(Figure 2B). To investigate further the effects of ESI on vesicular
trafficking, we examined anterograde transport in ESI-treated cells.
The mutant vesicular stomatitis virus glycoprotein tsO45 VSV-
G exhibits temperature sensitive transport from the ER to the cell
Figure 2. ESI treatment protects HeLa cells from SLTx, but not from ricin. A. ESI treatment reduces cellular protein synthesis levels.
Cells were treated with ESI or its inactive derivative ESR35 for 2, 3 or 5 h, and remaining protein synthesis ability was determined, shown relative to
control cells treated with the vehicle DMSO. N= 3, bars +/2 1 S.D. B. ESI treatment has no effect on ricin intoxication. Cells treated with DMSO
(open symbols), ESI (filled symbols, left-hand panel) or ESR35 (filled symbols, right hand panel) were challenged for 1 (circles), 2 (squares) or 4 h
(triangles) with graded doses of ricin and remaining protein synthesis levels were determined. Typical single assays are shown. C, D. ESI treatment
protects cells from SLTx challenge. Cells treated with DMSO, ESI or ESR35 were challenged with graded doses of SLTx for 1 (upper), 2 (middle) or
4 h (lower) and remaining levels of protein synthesis ability were determined. Typical single assays are shown in C, from which the IC50
(concentration of SLTx that reduced protein synthesis to half that of control non-toxin treated cells treated in parallel) values were determined, and
means of 3 or 4 independent experiments (+/2 1 S.D.) are shown in D, expressed as fold protection (IC50 drug treated cells: IC50 DMSO treated cells).
Protective effects from ESI and ESR35 treated cells were compared using an unpaired t-test (1 h, p = 0.0048, t = 4.358, n = 4; 2 h, p,.0001, t = 12.28,
n = 4; 4 h, p = 0.0377, t = 3.060, n = 3; *, significant: **, very significant: ***, extremely significant).
doi:10.1371/journal.pone.0022713.g002
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surface [49] and has become a classical marker for transit through
the secretory pathway [50]. At the restrictive temperature (40uC),
the protein is misfolded and cycles between the ER, the ER-Golgi
intermediate compartment (ERGIC) and the cis-Golgi network.
However, after a shift to the permissive temperature (32uC), it is
released from this cycle and is efficiently trafficked to the cell
surface [51]. This system provides an ideal platform from which to
investigate the effect of ESI on anterograde transport, indepen-
dently of any effects of the drug on protein synthesis (Figure 2A) or
on membrane integration [38].
Cells were infected with adenovirus encoding a GFP-tagged
tsO45 VSV-G (tsO45 VSV-G –GFP) and grown overnight at
40uC. Upon a temperature shift from 40uC to 32uC, tsO45 VSV-
G-GFP was released from the early secretory pathway, accumu-
lating in a peri-nuclear region by ,30 min and appearing
primarily at the cell surface after 1 to 2 hours in cells incubated
with DMSO or ESR35 (Figure 6A, DMSO and ESR35 panels). In
contrast, when cells were treated with the fungal metabolite
Brefeldin A (BFA), which blocks secretion by stimulating Golgi and
ER membrane fusion [52], [53], [54], tsO45 VSV-G-GFP
remained within the fused ER-Golgi compartment following the
temperature shift and did not reach the cell surface even after
2 hours (Figure 6A, BFA panels). In most ESI treated cells, the
bulk of the tsO45 VSV-G-GFP protein remained at an
intracellular location even after 2 hours, although some degree
of cell surface labeling was apparent at both 1 and 2 hours
(Figure 6A, ESI panels).
To underpin this microscopy-based analysis of VSV-G
trafficking, we also examined Golgi-dependent alterations in the
N-linked glycans of the VSV-G protein to investigate its progress
through the secretory pathway. During passage through the Golgi,
the N-linked glycans of VSV-G are modified such that they
acquire resistance to in vitro removal by the enzyme endoglycoside
H (EndoH) [55]. In lysates of HeLa cells expressing tsO45 VSV-
G, ESI treatment delayed the conversion of the glycoprotein into
an EndoH-resistant form, such that even after 2 hours a
population of EndoH-sensitive glycoprotein was still present
(Figure 6B, compare ESI with DMSO and ESR35). In the case
of BFA, we noted a more rapid acquisition of EndoH resistance
(Figure 6B, BFA) consistent with the entry of Golgi a-mannosidase
II (whose activity converts N-glycans from EndoH sensitivity to
resistance) into the ER upon BFA treatment [56]. Taken together,
these data indicate that the anterograde trafficking of VSV-G
through the secretory pathway, and its appearance at the cell
surface, are delayed by ESI treatment.
Finally, we examined the effects of ESI on the morphology of
organelles used by intracellular trafficking toxins. Typically, long
drug pretreatments (8–48 h) have been used in experiments that
demonstrate efficacy of ESI- in retarding the dislocation of an
ERAD substrate [34], inhibition of p97-associated functions [35],
and linkage of ER stress with activation of the ATF3 and ATF4
transcription factors [57]. However, even with exposures as short
as 1 hour, ESI exhibits biological activity, with clear effects on
protein translocation into the ER [38]. Immunofluorescence
Figure 3. ESI causes a delay in intoxication of HeLa cells with SLTx. A, B. The UPS has little influence on SLTx cytotoxicity. A. Cells
treated with the proteasome inhibitor clasto Lactacystin b-lactone (cLb-l) were challenged with SLTx for 1 (left), 2 (middle) or 4 h (right) and
remaining levels of protein synthesis were determined. B. Efficacy of cLb-l was confirmed in vitro by its ability to block degradation of casein
(arrowhead) in the presence of mammalian 26S proteasomes. C. Cells treated with ESR35 (left hand panel) or ESI (right hand panel) were challenged
with a fixed dose (1 mg.ml21) of SLTx for increasing periods and protein synthesis levels were determined. Exponential fits (dotted lines) were
extrapolated to determine the lag phase of intoxication (white arrowhead, DMSO; black arrowhead, drug). Typical single assays are shown. D. Lag
phases were determined as in C, and the half-lives of protein synthesis (T1/2) were determined from exponential fits in C. DMSO, n = 6, +/2 1.S.D., ESI
and ESR35, n = 3, +/2 1 S.D. Values were compared using unpaired t-tests. Lags: DMSO versus ESR35, no significant difference; DMSO versus ESI,
p,0.0001, t = 8.347; ESI versus ESR35 p = 0.0016, t = 7.658; **, very significant: ***, extremely significant. T1/2 values: no significant differences.
doi:10.1371/journal.pone.0022713.g003
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microscopy revealed that 8 h treatment with ESI resulted in
extensive vacuolation of the ER consistent with pathological effects
resulting from ER stress [58]. In contrast, there were no obvious
effects on lysosomal and Golgi morphology (Figure S1). Impor-
tantly, the effects of ESI treatment on the cytotoxicity of ER-
dislocating toxins shown here were performed at shorter time
intervals, specifically before any overt changes in cellular
morphology were apparent (data not shown).
Discussion
We show that ESI interferes with both anterograde and
retrograde transport of vesicular cargoes. Although no obvious
morphological changes to Golgi structure were seen even after
extended (8 hour) treatments of HeLa cells with ESI, we detected a
clear delay in the trafficking of VSV-G protein through the Golgi
and its subsequent appearance at the cell surface. The nature of
the VSV-G trafficking assay allows us to ascribe this as an effect on
vesicular transport, and this effect is consistent with our previous
observation that ESI treatment almost completely inhibits the
secretion of newly synthesized proteins from HepG2 cells [38].
When taken together with the data presented here, we conclude
that the strong ESI dependent inhibition of protein secretion that
we previously observed is most likely due to multiple effects, with
the drug reducing rates of protein synthesis (this study), affecting
Sec61-mediated translocation across the ER membrane [38] and
delaying subsequent vesicular transport to the cell surface (this
study).
ESI treatment was also found to inhibit the retrograde transport
of DTx to low pH endosomes. The initial stages of DTx uptake
rely on the endocytic pathway of the host cell, and our data
indicate that the effects of ESI with respect to DTx are at this early
stage of the process and not at the later membrane translocation
step (Figure 1).
In addition, ESI treatment inhibits the retrograde transport of
SLTx to and through the Golgi stack. Strikingly however, there
was no measurable affect on the cytotoxicity of ricin, which, like
SLTx, is thought to traffic via EE, the TGN and Golgi to the ER
(Figure 1). Despite the superficial similarities in retrograde
trafficking of ricin and SLTx, there are a number of characterized
differences, particularly during transit through the Golgi. Hence,
SLTx traverses the Golgi in a Rab6A’-dependent manner [59],
[60], [61], whilst ricin traffics through the Golgi in a Rab6A’-
independent manner [62]. Other differences include the strong
inhibition of SLTx trafficking but weak inhibition of ricin
trafficking by knockdown of syntaxin 5 [63] and the different
requirements for sorting nexins at the endosome-TGN interface
[64], [65], [66], [67]. Thus ESI does not act as a general inhibitor
Figure 4. ESI treatment interferes with retrograde trafficking of SLTx. A. Cells were treated with DMSO, ESI or ESR35 and then incubated for
increasing periods with Cy3-labelled SLTxB (red) or Cy2-labelled SLTx (green), after which they were fixed and examined by confocal microscopy.
Blue, DAPI-stained nuclei, white scale bar, 25 mm. B. Cells starved of sulphate were incubated with [35S]O4, treated with DMSO or ESI and then
incubated for increasing periods with a modified recombinant SLTxB pentamer, whose monomers bear a sulphation motif that is sulphated in the
trans-Golgi cisternae. SLTxB-sulf (arrowheads) was immunoprecipitated from detergent lysates of the cells and revealed after SDS-PAGE by
fluorography and autoradiography. C. Relative sulphation of SLTxB-sulf, determined from experiments performed in B, n = 3, +/2 1 S.D.
doi:10.1371/journal.pone.0022713.g004
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of vesicular trafficking, since at least one retrograde pathway is
unresponsive to treatment (see Figure 1). The substrate specificity
of ESI inhibition further underlines that there are multiple routes
or mechanisms by which exogenous toxins can reach the ER by
retrograde transport [68], [1].
ESI is unlikely to inhibit toxin action directly, since DTx and
SLTxA1 have different targets and mechanisms of action
(elongation factor-2 modification and ribosome modification,
respectively), and the rate of intoxication after the initial lag
phase is unaltered for both of these toxins. We cannot formally
exclude the possibility that one or more of the currently suggested
modes of action of ESI, namely interference with early dislocation
[34], p97-associated [12], [35] or ER translocation processes [38],
results in the selective inhibition of specific intracellular trafficking
routes. However, we found no effect of ESI treatment upon the
kinetics of dislocation of any of the toxins that we investigated in
this study. In the case of RTA and SLTxA, this suggests that the
ER-cytosol dislocation of both of these toxins does not involve the
early ESI inhibited step identified by Fiebiger and colleagues [34],
or either of the two proposed targets of ESI: p97 and the Sec61
translocon [12], [35], [38]. A recent report noted ESI-induced
cross-links between PDI and an ERAD substrate [39]. PDI is
thought to be responsible for the reductive cleavage of ricin,
releasing RTA chain from its RTB partner in the ER lumen, a
necessary prerequisite for the ER dislocation of the A chain [2],
[3]. Since ESI had no effect on the cytotoxicity of ricin, it seems
unlikely that it induced cross-links between RTA and PDI over the
short time scales used for cytotoxicity measurements. However, it
should be noted that the inhibitory effect of ESI when applied to
intact cells is incomplete [38]. Thus it is also conceivable that these
previously defined steps or components are perturbed by ESI, but
that they are not rate-limiting for toxin dislocation across the ER
membrane.
ESI has a bi-modular structure, with a comparatively hydro-
phobic portion that acts as a membrane binding domain [36] and
a 5-nitrofuran containing group that is required for its effects on
protein secretion and ER translocation [38], as well as p97
function [36]. ESR35, which lacks the nitrofuran group of ESI, was
ineffective in all of our assays. A number of studies have shown
that 5-nitrofuran containing compounds cause diverse effects in
biological systems including the inhibition of Salmonella growth [69]
and topisomerase function [70] and the induction of oxidative
stress [71]. Given these wide-ranging effects and the capacity of
nitrofurans to undergo in vivo modifications [72], we conclude that
the most likely explanation of our data is that ESI acts on one or
more currently unidentified components that function during
vesicular transport. The siRNA-mediated perturbation of signal
recognition particle-dependent protein targeting to the Sec61
translocon has been shown to result in selective defects in post-ER
membrane trafficking [73]. Hence the ESI dependent inhibition of
Figure 5. ESI treatment protects cells from DTx challenge. A. Typical single cytotoxicity profiles of DMSO, ESI and ESR35 treated HeLa cells
subsequently challenged with graded doses of DTx for 2 (upper) or 4 h (lower). B. Protective effect of the drugs, determined from assays in A. n = 3,
+/2 1.S.D. Protective effects from ESI and ESR35 treated cells were compared using an unpaired t-test (2 h, p = 0.0104, t = 4.555; 4 h, p = .00024,
t = 6.858; *, significant: **, very significant). C. Typical single assays showing the temporal profile of DTx cytotoxicity to cells treated with DMSO, ESI or
ESR35, and determination of the lag phase (dotted lines and arrowheads, coded as in Figure 3C). D. Lag phases and half-lives of protein synthesis (T1/2)
were determined. DMSO, n= 6, +/2 1.S.D., ESI and ESR35, n = 3, +/2 1 S.D. Values were compared using unpaired t-tests. Lags: DMSO versus ESR35, no
significant difference; DMSO versus ESI, p,0.0001, t = 8.810; ESI versus ESR35 p= 0.0028, t = 6.573; **, very significant: ***, extremely significant. T1/2
values: no significant differences.
doi:10.1371/journal.pone.0022713.g005
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Sec61 mediated translocation [38] could potentially contribute to
the effects that we report here. However, as we saw an inhibitory
effect within comparatively short timescales we believe it is more
likely that components involved in vesicular trafficking are affected
directly by ESI, rather than being depleted as a consequence of
any reduction in their synthesis or Sec61 mediated translocation.
Given the inhibitory effect of ESI upon p97-associated de-
ubiquitylation [35], [36], [37], one possibility is that the
compound may also impact one or more of the deubiquitinases
implicated in endocytosis [74].
In the original study by Fiebiger et al., [34] the authors found
that ESI inhibits both the human cytomegalovirus protein US11-
dependent degradation of MHC class I molecules, and the US11-
independent degradation of TCRa, a well-defined model for a
cellular ERAD substrate. The authors concluded that ESI inhibits
one or more stages just prior to, or concomitant with, dislocation
from the ER. Given that a number of ERAD substrates appear to
cycle between the ER and Golgi as a pre-requisite for subsequent
dislocation [75], [76], [77], [21], and evidence of cross-talk
between the secretory and ER degradative pathways [78], our new
data raise the possibility that a perturbation of vesicular transport
by ESI may also contribute to the drug’s inhibition of ER
associated protein degradation.
Materials and Methods
Cell culture
HeLa cells that reliably express the SLTx receptor Gb3 [47]
were used for all the cytotoxicity and SLTx trafficking experi-
ments. HeLa cells used for the VSV-G assays and the data shown
in Figure S1 were obtained from ATCC (CCL-2TM). Cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (DMEM/FCS), and
grown at 37uC in a 5% CO2 atmosphere.
Figure 6. ESI delays anterograde trafficking of tsO45 VSV-G-GFP. A. HeLa cells infected with adenovirus encoding tsO45 VSV-G-GFP were
grown overnight at 40uC, then pre-treated with DMSO, with 8 mM ESR35, ESI, or with 5 mg.ml
-1 Brefeldin A (BFA) for 1 h. Cells were then shifted to
32uC, and incubated for the time indicated in the continued presence of the compounds, prior to fixation and visualisation by fluorescence
microscopy. B. Lysates of HeLa cells treated as in A were incubated with Endoglycosidase H (EndoH, +) or mock treated (2), then analysed by
SDS-PAGE followed by immunoblotting using anti-VSVG antibody and alkaline phosphatase conjugated secondary antibody. The position of
N-glycosylated (CHO) and non-glycosylated VSV-G are indicated.
doi:10.1371/journal.pone.0022713.g006
Eeyarestatin 1 Inhibits Intracellular Trafficking
PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22713
Cytotoxicity experiments
Cytotoxicity experiments were performed on cells seeded at
26104 cells per well of a 96-well plate after overnight growth.
Growth medium was replaced by DMEM/FCS containing drug
(4 mM, from a stock dissolved in DMSO) or vehicle for 1 h. After
this pretreatment, the medium was replaced by serial dilutions of
toxin in DMEM/FCS containing either drug or vehicle as
appropriate, and after incubation (see Figures for toxin incubation
periods), the cells were rinsed in phosphate buffered saline, pH 7.4
(PBS) and incubated for 15 minutes in PBS containing 1 mCi.ml-1
[35S]-methionine/cysteine (Perkin Elmer). Wells were then rinsed
in PBS, and washed 5 times with cold 5% trichloroacetic acid.
After addition of 200 ml Optiphase supermix scintillant (Perkin
Elmer) to each drained well, and incubation at room temperature
(,2 h), radioactivity incorporated into acid-precipitable material
was determined by scintillation counting in a 1450 MicroBeta
Trilux scintillation counter (Perkin Elmer). In all cases, toxin
titration experiments for drug and vehicle were performed at the
same time on the same 96-well plate, to remove any differences
between plates. Data were normalized to coeval controls (nontoxin
treated cells pretreated and treated with drug or vehicle treated as
appropriate) and represent remaining protein synthesis (%).
Concentrations (IC50) of toxin that reduced protein synthesis
ability to 50% were determined using a median effect plot [79],
and protective effects were calculated as the ratio of IC50
drug:IC50 vehicle. For time course cytotoxicity experiments, cells
were treated with a fixed concentration (1 mg.ml21) of toxin for
increasing times (see Figures for details), but were otherwise
treated as above.
Microscopy
HeLa cells seeded at 26105 cells/well in 1 ml complete
DMEM/FCS were grown overnight on methanol-sterilised
coverslips in 12-well plates. They were then pre-treated with
0.1% DMSO, 4 mM ESI or 4 mM ESR35 for 1 hour and then
incubated in 250 ml ice-cold PBS (containing DMSO, ESI or
ESR35 as appropriate) and incubated with either Cy2-SLTx or
Cy3-SLTxB for 30 minutes at 4uC. The PBS was then replaced
with 1 ml of complete DMEM/FCS and incubated at 37uC and
cells were fixed using 4% paraformaldehyde (PFA) as part of a
time-course. The final time-point was fixed with 4% PFA at 37uC
for 20 minutes. Following fixing, PFA was quenched using 30 mM
glycine for 5 minutes and washed three times in PBS before
mounting using Vectashield mounting medium containing DAPI
(Vector Labs, Burlinghame, CA).
HeLa cells exposed to both Cy2-SLTx and Cy3-SLTxB were
imaged sequentially using Leica SP5 confocal microscopy. Cells
treated with Cy3-SLTx were imaged using the DPSS 561 laser
with an emission bandwidth between 566 nm to 790 nm (red) and
the 405 diode ultraviolet (UV) laser with an emission bandwidth
between 381 nm to 477 nm to image the nuclei (blue). The argon
laser (at 20%) was used to collect differential interface contrast
(DIC) images using the 488 nm laser. Cells treated with Cy2-
SLTxB were imaged using the argon laser (at 20%) utilizing the
488 nm laser with an emission bandwidth between 497 nm to
638 nm (green), also used to collect DIC images. Again the 405
diode UV laser with an emission bandwidth between 414 nm to
488 nm was used to image the nuclei (blue).
GFP-tagged VSV-G trafficking
HeLa cells seeded at 36105 cells/well in 2 ml complete
DMEM/FCS were grown overnight on methanol-sterilised
coverslips in 6-well plates and infected with adenovirus. Encoding
a GFP-tagged tsO45 VSV-G protein as described by Chui et al
[80]. Post-infection, the medium was replaced with fresh DMEM/
FCS and the cells were kept at 40uC overnight. The following day,
cells were pretreated for 1 h at 40uC in fresh carbonate free
medium containing DMSO (vehicle control), 8 mM ESI, 8 mM
ESR35 or 5 mg.ml
21 Brefeldin A as appropriate. The cells were
then shifted to the permissive temperature (32uC) and were fixed
as above after various lengths of incubation (see appropriate Figure
legends). Cells were mounted in Mowiol and imaged using an
Olympus BX60 upright microscope and Metamorph software
(Universal Imaging Corp.). Alternatively cells wre harvested in
Triton IP buffer (10 mM Tris-HCl pH 7.6, 140 mM NaCl, I mM
EDTA, 1% Triton x-100) and after a brief spin, the post-nuclear
supernatant. was split into two aliquots. One aliquot was
incubated overnight with 6670 U.ml21 of Endoglycosidase H as
directed by the supplier (New England Biolabs). Samples were
analysed by SDS-PAGE and immunoblotting with mouse anti-
VSV-G antibody followed by alkaline phospatase conjugated anti-
mouse-antibodiy (both from Sigma) and visualized by develop-
ment with BCIP/NBT colour development substrate (Promega).
SLTx and SLTxB labeling with Cy dyes
Purified SLTx and SLTxB were labeled according to the
manufacturer’s instructions (GE Healthcare).
SLTxB sulfation assay
Cells were seeded at 106 per well in six-well plates, grown
overnight and washed twice in sulfate-free DMEM (Gibco) lacking
FCS. They were then incubated for 3 h, 37uC in sulfate-free
medium lacking FCS in the presence of 200 mCi.ml21 [35S]-SO4.
During the last hour of this period, cells were treated with drug or
vehicle as appropriate. SLTxB (1 ml, 1 mg.ml21) was added to
wells and incubation continued for a time-course (see Figures and
legends). Cells were then washed twice with cold PBS and scraped
into 1 ml of lysis buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-
100) containing protease inhibitor cocktail (Roche). Cell debris was
removed by brief centrifugation (1 minute, 14,000 rpm, in a
microfuge) and SLTxB chain was immunoprecipitated from the
soluble fraction with sheep anti SLTxB and proteinA-Sepharose at
4uC overnight and washed as previously described [3]. Sulfated
SLTxB was identified by autoradiography after SDS-PAGE [81]
of the immunoprecipitated material.
Casein degradation assays
Human erythrocyte 26S proteasomes (10 nM, Enzo Life
Sciences) were pre-incubated in 20 mM Hepes pH 7.6, 4 mM
ATP, 10 mM MgCl2, 1 mM DTT containing 20 mM clasto-
Lactacystin b-lactone (Merck) or its vehicle DMSO for 30 minutes
at 24uC before addition of 5 mM b-casein (Sigma-Aldritch). After
incubation (4 h, 37uC), the samples were subjected to SDS-PAGE
and immunoblotting. Casein was revealed by sequential incuba-
tions of the blot with sheep anti-casein antibodies (Thermo
Scientific) and donkey anti-sheep antibodies conjugated to alkaline
phosphatase (Sigma Aldrich) followed by development with BCIP/
NBT colour development substrate (Promega).
Supporting Information
Figure S1 Effect of ESI on subcellular morphology. HeLa
cells were treated with 8 mM ESR35 or ESI, or left untreated (UT)
for 8 h, then fixed with methanol. Different subcellular compart-
ments were visualised by labelling with anti-PDI (ER), anti-
LAMP1 (lysosomes) or anti-Golgin 84 (Golgi appuratus), followed
by fluorescently labelled secondary antibodies.
(TIF)
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